Amino acid derivative supplement
Creatine monohydrate
Creatine monohydrate after one dose: 50% at ~3 h, 25% at 6 h, 12.5% at 9 h.
Drawn from the half-life in the app's model, ~3 h. The model's figures
- Compound
- Creatine monohydrate
- Symbol
- CRE
- Family
- Supplements
- Parts
- 14
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

4%The 18th most tracked compound in Milligram: of people who track compounds in Milligram logged Creatine monohydrate in the last 90 days.
Schedule
Logged doses
Half of people logged between 5 and 10 g per dose; the median was 9 g.
Tracked alongside
The share of people logging Creatine monohydrate who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
Creatine is a naturally occurring non-protein amino acid compound found primarily in red meat and seafood, and about 95% of the body's creatine is in skeletal muscle.1 In a position stand published in the Journal of the International Society of Sports Nutrition in 2017, Kreider and colleagues write that about half of the daily need for creatine comes from the diet, with the rest synthesized primarily in the liver and kidneys from arginine and glycine.1 The app lists creatine as an amino acid derivative in its supplement group and grades the evidence as strong. That grade is the app's own; the same authors write that studies "have consistently shown that creatine supplementation increases intramuscular creatine concentrations", while the Parkinson disease trial (1741 people) and the Huntington disease trial (553 people), both stopped early for futility, did not report benefit on their primary outcomes.1,2,3
Kreider and colleagues write that "over 1,000 studies have been conducted" on creatine monohydrate since the early 1990s.1
The position stand's conclusion on performance reads: "Creatine monohydrate is the most effective ergogenic nutritional supplement currently available to athletes with the intent of increasing high-intensity exercise capacity and lean body mass during training".1 The paper states that support to prepare it came from the Council for Responsible Nutrition, and several authors declare ties to companies that sell creatine or related products; the analysis of the paper below sets out both.1
How it works
Sources in this part
The primary metabolic role of creatine, Kreider and colleagues write, is to combine with a phosphoryl group to form phosphocreatine through creatine kinase, and the energy released when phosphocreatine is split can serve as a buffer to resynthesize ATP.1 On a normal diet, they write, muscle creatine stores are about 60–80% saturated, and supplementation raises muscle creatine and phosphocreatine by 20–40%.1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~3 h
- Bioavailability
- 99%
- Typical dose
- 5–10 g/day
- Route
- Oral
- Time to peak
- ~1.5 h
None of the sources cited here reports a plasma half-life of creatine, and the app's figure of about 3 hours stands without a sourced figure beside it. The full texts read were the position stand, CREST-E, Antonio and colleagues, Chilibeck and colleagues and Xu and colleagues; the NET-PD trial, the Persky review and the studies of Harris and of Hultman were read as indexed records only, so the full Persky review is not covered. Persky and colleagues write that "there are very limited pharmacokinetic data available for creatine".5
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 3 hours | No half-life reported in the texts read, which for the Persky review were the indexed record only5 |
| Bioavailability | 99% by mouth | Absorption into the blood "is nearly 100%" per Kreider and colleagues1; crushed lozenge or crystalline suspension gave a 20% lower peak and a 30-35% smaller area under the curve than the same dose in solution6 |
| Time to peak | About 1.5 hours | About 60 minutes after an oral dose per Kreider and colleagues1; after 5 g, a mean peak at 1 hour of 795 (SD 104) µmol/l in three subjects7 |
| Typical dose | 5 to 10 g/day | Maintenance of 3–5 g/day, with 5–10 g/day in some larger athletes, per Kreider and colleagues1; the EU health claim text refers to a daily intake of 3 g8 |
| Muscle saturation | App note: stores saturate over 2 to 4 weeks | 3–5 g/day raises muscle stores over a 3–4 week period per Kreider and colleagues1 |
In the 1992 study by Harris, Söderlund and Hultman at the Karolinska Institute, repeated 5 g doses every 2 hours sustained plasma creatine at around 1000 µmol/l.7 Supplementation with 5 g four or six times a day for 2 or more days raised quadriceps total creatine significantly in 17 subjects, by as much as 50% in some, most in those with a low initial content.7 The indexed record of that study lists the publication type "Research Support, Non-U.S. Gov't" and no funding statement, and is cut off after 250 words.7 Harris and colleagues of University College Chichester reported in 2002, in five non-users, "approximate bioequivalence of creatine contained in meat with the same dose supplied in a solution", with a lower but longer-maintained peak after meat.6 The indexed records of that study and of the Persky review list the same publication type, with no funding statement.5,6
The chart is a model drawn from the app's half-life and time to peak, with the one interval the cited studies report in daily terms: 3 g/day in the 1996 loading study.9 The model assumes the app's 3 hour half-life and linear kinetics, which Persky and colleagues say do not describe creatine, and it shows plasma, not muscle, levels.5
Level over 3 days
Level, as a share of the peak after one 3 g dose
As studied: every day9. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).
An illustration from a pharmacokinetic model using a half-life of 3 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Hultman and colleagues, 19969 | Clinical trial with muscle and urine measures | 31 male subjects | 20 g/day for 6 days, then 2 g/day for 30 days; 3 g/day for 28 days | Muscle total creatine rose by about 20% after 6 days; the rise was similar but more gradual with 3 g/day |
| Chilibeck and colleagues, 201710 | Meta-analysis of 22 randomised trials | 721 participants, mean age 57–70 across studies; 15 studies in healthy older adults, 2 in frail older adults, 1 each in people with heart disease, Parkinson disease, chronic obstructive pulmonary disease, type 2 diabetes and osteoarthritis | Creatine or placebo during resistance training 2–3 days/week for 7–52 weeks; 8 studies used a 20 g/day loading phase for 5–7 days; 3 to 5 g/day thereafter and in the rest | Greater increase in lean tissue mass than placebo, mean difference 1.37 kg (95% CI 0.97–1.76); chest press strength SMD 0.35 (0.16–0.53); leg press strength SMD 0.24 (0.05–0.43) |
| Xu and colleagues, 202411 | Systematic review and meta-analysis of 16 randomised trials | 492 participants aged 20.8–76.4 years; 13 studies in healthy people and 3 in people with specific conditions | Creatine monohydrate in all included studies; dose varied by study; 9 studies under 4 weeks, 7 longer | Memory SMD 0.31 (95% CI 0.18–0.44); attention time SMD -0.31 (-0.58 to -0.03); processing speed time SMD -0.51 (-1.01 to -0.01), a negative value meaning a shorter task time; no significant effect on attention scores (SMD 0.22, p = 0.49), processing speed scores (SMD 0.01, p = 0.97), executive function time, overall cognitive function or executive function, or on attention time in healthy people (SMD -0.18, p = 0.44) |
| NET-PD LS-1, JAMA, 20152 | Randomised, double-blind, placebo-controlled, 45 sites | 1741 people with early, treated Parkinson disease | Creatine 10 g/d or placebo, planned minimum 5 years (maximum follow-up 8 years) | Stopped early for futility at the interim analysis of 955 people (median follow-up 4 years); mean summed ranks (higher is worse) 2414 on creatine and 2360 on placebo, P = .45 |
| CREST-E, Neurology, 20173 | Randomised, double-blind, placebo-controlled, 46 sites | 553 people with early Huntington disease (275 creatine, 278 placebo) | Up to 40 g daily of creatine monohydrate, up to 48 months | Halted for futility; decline in total functional capacity 0.82 points a year on creatine and 0.70 on placebo |
The disclosure statement of Chilibeck and colleagues reads "The authors report no conflicts of interest in this work".10 Most studies in that analysis reported no adverse effects; four reported gastrointestinal events and two reported muscle cramping.10 Xu and colleagues state that their funding came from the National Natural Science Foundation of China (Project No. 72364006), and list among their limits that the included studies "exhibited heterogeneity in design, sample size, and testing methods".11 The paper reports memory as 24 studies with 1,000 participants, against 16 trials and 492 participants overall.11
Deeper analysis: the ISSN position stand, 2017
The position stand by Kreider and colleagues, from groups including Texas A&M University, Nova Southeastern University and the University of Regina, reviews the literature on creatine in exercise, sport and medicine and updates the International Society of Sports Nutrition's position.1 It states that after loading "performance of high intensity and/or repetitive exercise is generally increased by 10–20% depending on the magnitude of increase in muscle PCr".1 The paper names the Council for Responsible Nutrition as the source of support and states that Kreider "prepared this position stand update at the request of the Council for Responsible Nutrition and ISSN".1 Its competing-interests statement says Kreider "has received externally-funded grants from industry to conduct research on creatine", serves as a scientific and legal consultant and is a university approved scientific advisor for Nutrabolt; Antonio is chief executive and co-founder of the ISSN; Almada is chief executive of Vitargo Global Sciences and Wildman chief science officer of Post Active Nutrition; Kalman's contract research organization and Lopez have received research grants from companies that sell creatine; Kalman sits on an advisory board (Post Holdings) to Dymatize, which sells creatine; Lopez co-founded Supplement Safety Solutions and serves as an independent consultant to companies that sell creatine; and Ziegenfuss receives royalties from the sale of several sports nutrition products.1 The paper has no section on its own limitations; its closing statement of the position is "Further research is warranted to examine the potential medical benefits of creatine monohydrate and precursors like guanidinoacetic acid on sport, health and medicine".1
Deeper analysis: Hultman and colleagues, Journal of Applied Physiology, 1996
Hultman, Söderlund, Timmons, Cederblad and Greenhaff, working from Nottingham, studied 31 male subjects who ingested creatine in different quantities over varying periods, measuring muscle creatine, its later decline and urinary creatinine.9 Muscle total creatine rose by approximately 20% after 6 days at 20 g/day, stayed raised on 2 g/day for a further 30 days, and without that dose declined until, 30 days after stopping, it "was no different from the presupplementation value".9 A similar but more gradual 20% increase occurred over 28 days at 3 g/day, and the authors conclude that 3 g creatine/day "in the long term" is "likely to be as effective at raising tissue levels as this higher dose".9 The indexed record of the paper lists no funding statement, author ties or limitations, and the full paper was not read.9
Deeper analysis: CREST-E, Neurology, 2017
Hersch and colleagues of Massachusetts General Hospital, the University of Rochester and the NIH randomised 553 people with early Huntington disease (TFC of 7 or more) to creatine (275) or placebo (278) at 46 sites, with doses titrated to the highest tolerated, 5 to 40 g daily.3 The primary outcome was the annual rate of change in total functional capacity, and the trial was halted at the first interim analysis, when the futility criterion was reached, short of the 650 planned.3 The estimated decline was 0.82 points a year on creatine and 0.70 on placebo, a difference of 0.12 points a year (nominal 95% confidence limits −0.11 to 0.35) favoring placebo.3 Among 41 secondary and exploratory measures, "none showed even nominally significant differences between treatment groups".3 A prespecified subgroup analysis found a treatment-by-sex interaction: among women the rate of decline was 0.42 points a year greater on creatine (p = 0.0028), and among men 0.25 points a year less (p = 0.12).3 Premature withdrawals were 97 participants (35%) on creatine and 72 (26%) on placebo; adverse events, mainly gastrointestinal, were significantly more common on creatine; serious adverse events were more frequent on placebo (78 among 48 participants) than on creatine (62 among 42); and 7 of the 9 deaths occurred on placebo.3 The analysis excluded 16 participants at one site because of Good Clinical Practice concerns.3 The authors list their own limits: enrolment difficulties led to a redesign and endpoint revision that "reduced the potential power to detect a small reduction in the rate of TFC decline", the burden of the study contributed to "the substantial withdrawal rate", and on blinding "we were not completely successful".3 Funding came from NIH cooperative agreements (the National Center for Complementary and Integrative Health, the Office of Dietary Supplements, NINDS) and the FDA Orphan Products Division, and the creatine monohydrate was manufactured by AlzChem GmbH and packaged by Deseret Laboratories.3 The disclosures list grant support from the NIH, the FDA and others and consulting fees from companies including Azevan, Link Medicine, Mitochon Pharmaceuticals, Pfizer, PRANA, Wave Life Sciences, Voyager Therapeutics, Raptor Pharmaceuticals and Borvo-Lenus Pharmaceuticals; the statement names no creatine seller.3
The NET-PD LS-1 trial reported a primary outcome built from five measures and analysed with one global test, which showed no difference between creatine and placebo in the 955 people analysed, and "no detectable differences" in adverse and serious adverse events by body system at its chosen threshold.2 It is registered as NCT00449865 and its listed grants are from NIH institutes; the indexed record lists consulting and grant ties of several authors to pharmaceutical companies and does not say who supplied the creatine, and it gives no limitations text.2
Doses reported in studies
The app lists a typical dose of 5 to 10 g/day.
| Source | People | Dose | Length | Note |
|---|---|---|---|---|
| Hultman and colleagues, 19969 | 31 men | 20 g/day, then 2 g/day; 3 g/day | 6 days, then 30 days; 28 days | Muscle total creatine up about 20% |
| Kreider and colleagues, 20171 | Not specified (5–10 g/day for some larger athletes) | 5 g four times daily or about 0.3 g/kg, then 3–5 g/day | 5–7 days, then maintenance | 3 g/day for 28 days is the slower alternative the paper describes |
Sources in this part
Side effects reported
Sources in this part
Kreider and colleagues write that "the only consistently reported side effect from creatine supplementation that has been described in the literature has been weight gain".1 Antonio and colleagues state that the initial loading phase (20 g/day for 5 to 7 days) "typically results in a 1-3 kg increase in body mass, mostly attributable to net body water retention", note that water retention in the first several days does appear to be the most common adverse effect, and also state that creatine supplementation "does not always lead to water retention".4 Their funding statement reads "Not applicable".4 Their competing-interests statement says Antonio is chief executive officer of the ISSN, "an academic non-profit that receives support and/or sponsorship from companies that manufacture and/or sell creatine or creatine-containing products"; that Kreider, Candow, Gualano, Rawson and Smith-Ryan serve on the scientific advisory board for Alzchem, a company that manufactures creatine; that Candow was previously chief scientific officer of a company that sells creatine products; and that VanDusseldorp advises supplement companies that sell creatine.4 Each question was answered by one author; Antonio, Kreider and Ziegenfuss also wrote the position stand, and Candow the Chilibeck meta-analysis.4 In CREST-E, at up to 40 g daily, adverse events were mainly gastrointestinal and significantly more common on creatine, and "transient increases in creatinine levels" and "mild, unexplained, asymptomatic elevations of creatine phosphokinase" were noted on creatine, while neither weight gain nor weight loss was observed on creatine.3
On the kidneys, Antonio and colleagues conclude that creatine, "when ingested at recommended dosages, does not result in kidney damage and/or renal dysfunction in healthy individuals".4 They write that the origin of the concern is unknown and could be traced to a poor understanding of creatine and creatinine metabolism and to a 1998 case study of a young man with focal segmental glomerulosclerosis who had been treated with cyclosporine for 5 years, and that a small number of later case reports were confounded by medications, pre-existing kidney disease, other supplements, inappropriate doses such as 100 times the recommended amount and anabolic steroid use.4 On hair loss, Antonio and colleagues describe one study by van der Merwe and colleagues in which serum dihydrotestosterone rose by 56% after a 7-day load of 25 g/day and stayed 40% above baseline after 14 days at 5 g/day. They write that the results "have not been replicated", that total testosterone did not rise in the 16 males who completed the study, that dihydrotestosterone stayed within normal clinical limits, that its baseline was 23% lower in the creatine group, and that "no study has reported hair loss/baldness in humans". Of 12 other testosterone studies, ten found no change and two small, physiologically insignificant rises, and they conclude that "The majority of available evidence does not support a link between creatine supplementation and hair loss / baldness".4
Bloodwork and markers
Sources in this part
The app lists no markers to monitor for creatine. The marker the sources discuss is creatinine, which Antonio and colleagues say relates to muscle mass and to dietary creatine and creatinine intake, and which "may be increased by ingestion of creatine supplementation and creatine containing foods, such as meat".4 In a review of creatine studies that they cite, Persky and Rawson found no rise in serum creatinine in 12 studies, a rise within the normal range in 8 and a rise above normal limits in 2, one of which did not differ from control.4 In CREST-E a serum creatinine above 2.0 mg/dL led to dose suspensions, and permanent discontinuations and temporary suspensions were more common on creatine, the latter mainly because of creatinine elevations.3
Regulatory and anti-doping status
Sources in this part
The annex to Commission Regulation (EU) No 432/2012, as published on legislation.gov.uk, lists the claim "Creatine increases physical performance in successive bursts of short-term, high intensity exercise", with the condition that "The claim may be used only for food which provides a daily intake of 3 g of creatine" and only for foods targeting adults performing high intensity exercise; it cites EFSA Journal 2011;9(7):2303.8 A second entry, inserted by Commission Implementing Regulation (EU) 2017/672 of 7 April 2017, reads "Daily creatine consumption can enhance the effect of resistance training on muscle strength in adults over the age of 55", for adults engaged in regular resistance training, with the same 3 g daily intake, resistance training at least three times per week at an intensity of at least 65%-75% of one repetition maximum load, and an EFSA Journal citation of 2016;14(2):4400.8 The text is as published on legislation.gov.uk; an Official Journal copy of the regulation was not read.8 A text search of the World Anti-Doping Agency's 2026 Prohibited List on 16 November 2026 found no occurrence of the word creatine.12 The list's classes are open-ended, so a word search does not show how any substance is treated.12 Kreider and colleagues wrote in 2017 that creatine "is not banned by any sport organization although some organizations prohibit provision of some types of dietary supplements to athletes by their teams".1 No assessment by the US FDA or Australia's TGA is cited here.
What is not known
The sources cited here report no plasma half-life of creatine, though the Persky review, the NET-PD trial and the Harris and Hultman studies were read as indexed records only, and Persky and colleagues write that "the relationship between plasma creatine and muscle creatine needs to be elucidated".5 The Parkinson disease and Huntington disease trials above reported no benefit on their primary outcomes, and CREST-E's sex-by-treatment finding came from a subgroup analysis in a trial that did not reach its planned enrolment.2,3 In the cognition meta-analysis, the certainty of evidence was moderate for memory, low for processing speed, and low to very low for overall cognitive function, executive function and attention.11 Kreider and colleagues write that the majority of studies were conducted on men and that some studies suggest women may not see as much gain in strength and muscle mass during training.1
Frequently asked questions
What is the half-life of creatine?
No plasma half-life of creatine is reported in the sources cited here, though the Persky review was read as an indexed record only, and the app lists about 3 hours. Persky and colleagues describe creatine pharmacokinetics as nonlinear with respect to dose size and frequency.5
Is creatine banned by WADA?
The 2026 WADA Prohibited List text contains no occurrence of the word creatine in a search made on 16 November 2026, and the list's classes are open-ended, so a word search does not show how any substance is treated.12 Kreider and colleagues wrote in 2017 that creatine use "is not banned by any sport organization".1
How long does it take for muscle creatine to rise?
In Hultman and colleagues' 1996 study of 31 men, muscle total creatine rose by approximately 20% after 6 days at 20 g/day.9 A similar but more gradual 20% rise occurred over 28 days at 3 g/day.9 Kreider and colleagues put the rise from supplementation at 20–40%, and write that 3–5 g/day raises stores over a 3–4 week period, while 5 g four times daily for 5–7 days is the "most effective way".1
Is a creatine loading phase needed?
Antonio and colleagues conclude that "a creatine 'loading' phase is not required" because 3–5 g/day also raises muscle stores.4
Does creatine damage the kidneys?
Antonio and colleagues conclude that at the doses they call recommended (3-5 g/day or 0.1 g/kg of body mass a day) it does not result in kidney damage or renal dysfunction in healthy individuals.4
Does creatine cause hair loss?
Does creatine cause water retention?
Guides, tools and comparisons
References
- Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr 2017. PMC5469049
- NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 2015. PMID 25668262
- Hersch SM, Schifitto G, Oakes D, et al. The CREST-E study of creatine for Huntington disease: a randomized controlled trial. Neurology 2017. PMC5562960
- Antonio J, Candow DG, Forbes SC, et al. Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show? J Int Soc Sports Nutr 2021. PMC7871530
- Persky AM, Brazeau GA, Hochhaus G. Pharmacokinetics of the dietary supplement creatine. Clin Pharmacokinet 2003. PMID 12793840
- Harris RC, Nevill M, Harris DB, et al. Absorption of creatine supplied as a drink, in meat or in solid form. J Sports Sci 2002. PMID 11811571
- Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci 1992. PMID 1327657
- European Commission. Commission Regulation (EU) No 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods. Annex, as published on legislation.gov.uk. legislation.gov.uk
- Hultman E, Soderlund K, Timmons JA, et al. Muscle creatine loading in men. J Appl Physiol 1996. PMID 8828669
- Chilibeck PD, Kaviani M, Candow DG, Zello GA. Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis. Open Access J Sports Med 2017. PMC5679696
- Xu C, Bi S, Zhang W, Luo L. The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis. Front Nutr 2024. PMC11275561
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026